Cytokinetics may be counting down the days until the FDA decides whether to approve its cardiovascular drug aficamten. But, for a biotech planning to commercialize its first drug—and without Big ...

Bristol Myers Squibb announced the presentation of data from its cardiovascular portfolio at the American Heart Association’s ((AHA) Scientific Sessions 2025, taking place November 7–10, 2025 in New ...

NEW YORK - Bristol Myers Squibb (NYSE:BMY), a pharmaceutical giant with a market capitalization of $93.79 billion and currently considered undervalued according to InvestingPro analysis, will present ...

Bristol Myers Squibb Showcases New Long-Term and Real-World Data From Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2025 Multiple real-world analyses and an analysis ...

Camzyos (mavacamten) is a brand-name capsule that’s prescribed for obstructive hypertrophic cardiomyopathy in adults. It has a boxed warning about the risk of heart failure. To help manage this, the ...

Bristol Myers Squibb Co. (NYSE:BMY) reported third-quarter 2025 revenues of $12.22 billion on Thursday, beating the consensus of $11.81 billion, a 3% increase year over year. Growth Portfolio revenues ...

Please provide your email address to receive an email when new articles are posted on . Mavacamten did not improve outcomes vs. placebo at 48 weeks in patients with nonobstructive hypertrophic ...

Bristol Myers Squibb Presents Real-World Outcomes of Camzyos (mavacamten) Across Four Continents at the European Society of Cardiology (ESC) Congress 2025 Findings from COLLIGO-HCM reinforce Camzyos’ ...

Doctors prescribe Camzyos to treat obstructive hypertrophic cardiomyopathy with symptoms in adults. It’s available only under the Camzyos risk evaluation and mitigation strategy (REMS) program, a ...

FDA lowers echo monitoring to every 6 months for select Camzyos patients in maintenance phase. Camzyos label update removes prior contraindications with certain CYP inhibitors. See the trading ...